SK pharmteco, is pleased to announce $35m investment for the initial phase of an expansion plan for SK biotek Ireland’s Dublin-based pharmaceutical manufacturing plant.

SK pharmteco, is pleased to announce $35m investment for the initial phase of an expansion plan for SK biotek Ireland’s Dublin-based pharmaceutical manufacturing plant.
Pfizer Inc. has planned a $120 million investment at its Kalamazoo manufacturing facility to support the production of its COVID-19 antiviral treatment, Paxlovid.
The new Biomerics office will be equipped with multiple balloon-forming machines, state-of-the-art test equipment, and a cleanroom that is ISO 13485:2016 certified.
The ISO 7 class clean room can produce nine-layer blown film. The new installation fully encloses commercial-scale production of Berry’s proprietary nine-layer blown film from extrusion to packaging, a first in the United States. The addition further enhances Berry’s ability to supply more sensitive applications such as sterile intravenous solution bags, pharmaceutical packaging, medical equipment manufacturing, and microchip packaging.
Foxx Life Sciences celebrates two new manufacturing facilities in Londonderry, New Hampshire and Hyderabad, India.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications…
Exyte has successfully completed the construction of the first ExyCell® facility in China, the CliniMACS Cell Factory® of Miltenyi Biotec, a global provider of integrated solutions for Advanced Therapy Medical Products (ATMPs). The patented ExyCell technology was developed by Exyte as an end-to-end, integrated facility solution with standardized and modularized elements. These pre-configured and pre-fabricated modules enable fast-track construction thereby shortening time-to-market for new therapeutics and vaccines. The ExyCell facility is installed on the fourth floor of the ATLATL building located in the Zhangjiang High-Tech Park, and Miltenyi Biotec is now transferring production technology from Germany to China with regular operations for ATMP production is expected by autumn 2021. The facility will soon be open to visitors by appointment.
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health for three state-of-the-art cleanrooms…
WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany. The permit successfully demonstrates for the first time that Premier Quality together with Record Speed WuXi Biologics consistently delivered in China can also be applied in global countries.
Quattroflow, part of PSG and Dover (NYSE: DOV), announced that it will increase manufacturing capacity for its single-use quaternary diaphragm pumps with the construction of a new ISO Class 7 cleanroom.
Expected to open in October 2021, the additional cleanroom will more than double the Quattroflow cleanroom space in Duisburg, Germany.
PAJUNK, a leading global provider of medical devices, moved into its new headquarters, located in Alpharetta, GA, just north of Atlanta. The 50,000 square foot building houses new office space, a state-of-the-art clean room for manufacturing procedural trays, and a 30,000 square foot warehouse. The increased space is designed to keep up with growing demands while providing best-in-class customer service.
Novo Holdings today announced that it has co-led with Vivo Capital the over-subscribed US$200 million Series A and Crossover round in Esco Lifesciences Group (“Esco”), a leading provider of life sciences tools and services. The financing will enable Esco to strengthen its position through organic and external growth and transformation, as well as invest in China, thus addressing some of the most dynamic market segments and geographies. Other investors include two Asian sovereign wealth funds and Singapore-based global investor, EDBI.